-
公开(公告)号：US06642014B1
公开(公告)日：2003-11-04
申请号：US09395017
申请日：1999-09-13
申请人： Henrik Pedersen , Swen Hölder , Jørgen Kjems , Mette Lund
发明人： Henrik Pedersen , Swen Hölder , Jørgen Kjems , Mette Lund
IPC分类号： G01N33573
CPC分类号： C40B40/02 , C07K2319/00 , C12N9/20 , C12N9/22 , C12N9/2437 , C12N15/1034 , C12N15/1037 , C12N15/113 , C12N2310/121 , C12Q1/00
摘要： A method for in vitro selection, from a library of catalyst molecules, of a catalyst molecule of interest having a relatively more efficient specific catalytic activity of interest, as compared to the rest of the catalyst molecules within said library, and wherein said in vitro selection method is characterised by that it allows multiple catalytic activity turn-overs (i.e. substrate to product catalytic activity turn-overs), by the catalyst molecule of interest, before it is finally collected.
摘要翻译： 与所述文库中的其余催化剂分子相比，从感兴趣的相对更有效的特定催化活性的目的催化剂分子的催化分子的文库中体外选择一种方法，其中所述体外选择 方法的特征在于，在最终收集之前，其通过感兴趣的催化剂分子允许多重催化活性翻转（即底物至产物催化活性翻转）。
-
公开(公告)号：US20150299702A1
公开(公告)日：2015-10-22
申请号：US14648360
申请日：2013-11-29
申请人： Peter Samuel WULFF , Mogens TERGÅRD DUCH , Shervin BAHRAMI , Jørgen KJEMS , Hansen Thomas BIRKBALLE
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/113 , C12N2310/51 , C12N2310/532 , C12N2320/30 , C12N2330/10 , C12N2330/51 , Y02A50/465
摘要： The present invention relates to inhibition of microRNAs (miRNA), other types of RNA and RNA-binding proteins. In particular the present invention relates to nucleic acid sequences that are circular and allow inhibition of the interactions between microRNAs and their RNA target and being resistant to degradation by exonucleases. Also, the present invention relates to nucleic acid sequence that are circular and acts as an RNA blocker or protein decoy.
摘要翻译： 本发明涉及抑制微小RNA（miRNA），其他类型的RNA和RNA结合蛋白。 特别地，本发明涉及环状的核酸序列，并允许抑制微小RNA及其RNA靶标之间的相互作用并且对外源核酸酶的降解具有抗性。 此外，本发明涉及环状并作为RNA阻断剂或蛋白质诱饵的核酸序列。
-
公开(公告)号：US20120040004A1
公开(公告)日：2012-02-16
申请号：US13146498
申请日：2010-01-28
申请人： Kenneth Alan Howard , Jørgen Kjems , Isabel Nawroth , Jan Alsner , Jens Overgaard , Flemming Besenbacher
发明人： Kenneth Alan Howard , Jørgen Kjems , Isabel Nawroth , Jan Alsner , Jens Overgaard , Flemming Besenbacher
IPC分类号： A61K31/713 , A61P43/00 , A61K9/14 , B82Y5/00
CPC分类号： C12N15/113 , A61K9/5161 , C12N15/111 , C12N2310/14 , C12N2320/32
摘要： The present invention relates to treatment or prevention of radiation induced fibrosis using TNF-alpha antagonism. Preferably, TNF-alpha is antagonized by direct binding or by inhibition of synthesis. In a preferred embodiment, the invention comprises intraperitoneal administration of a chitosan-siRNA nanoparticle, wherein the siRNA is targeted to the mRNA encoding TNF-alpha.
摘要翻译： 本发明涉及使用TNF-α拮抗作用来治疗或预防辐射诱导的纤维化。 优选地，通过直接结合或抑制合成来拮抗TNF-α。 在优选的实施方案中，本发明包括腹膜内施用壳聚糖-siRNA纳米颗粒，其中siRNA靶向编码TNF-α的mRNA。
-
公开(公告)号：US20110033547A1
公开(公告)日：2011-02-10
申请号：US12667204
申请日：2008-07-04
IPC分类号： A61K9/14 , A61K31/713 , A61K39/395 , A61K38/40 , B82Y5/00 , B82Y40/00
CPC分类号： A61K48/0041 , A61K9/5161 , C12N15/111 , C12N2310/14 , C12N2320/51
摘要： The present invention relates to dehydrated nanoparticles comprising chitosan and a nucleic acid. Preferably, the nucleic acid is a siRNA. Dehydrated nanoparticles of the invention have improved storage characteristics. The particles may be used in screening methods, e.g. where they have been dried onto a solid support, such as the surface of a culture well. The nanoparticles may also be dried onto implants for tissue engineering scaffolds, where they enable transfection of cells growing on the scaffold. Moreover, the particles have therapeutic relevance.
摘要翻译： 本发明涉及包含壳聚糖和核酸的脱水纳米粒子。 优选地，核酸是siRNA。 本发明的脱水纳米颗粒具有改善的储存特性。 颗粒可用于筛选方法，例如， 它们已经被干燥到固体支持物上，例如培养物的表面。 纳米颗粒也可以干燥到用于组织工程支架的植入物上，其中它们能够转染在支架上生长的细胞。 此外，颗粒具有治疗相关性。
-
公开(公告)号：US20140350680A1
公开(公告)日：2014-11-27
申请号：US14367870
申请日：2012-12-22
申请人： Dang Quang Svend Le , Muwan Chen , Menglin Chen , Anette Overgaard Baatrup , Cody Eric Bünger , Helle Lysdahl , Jørgen Kjems , Morten Østergaard Andersen , Flemming Besenbacher
发明人： Dang Quang Svend Le , Muwan Chen , Menglin Chen , Anette Overgaard Baatrup , Cody Eric Bünger , Helle Lysdahl , Jørgen Kjems , Morten Østergaard Andersen , Flemming Besenbacher
CPC分类号： A61L27/14 , A61F2/105 , A61F2/28 , A61L27/34 , A61L27/50 , A61L29/085 , A61L29/14 , A61L31/10 , A61L31/14 , A61L2400/18
摘要： The present invention relates to a process for modifying the surface morphology of a medical device. The modified surface has, among other advantageous properties, an improved capacity for sorption or conjugation of a variety of bioactive agents, the addition of which will turn the medical device into a localized drug delivery system.
摘要翻译： 本发明涉及用于改变医疗装置的表面形态的方法。 改进的表面除了其它有利的性质之外还具有改进的各种生物活性剂的吸附或缀合的能力，其添加将将医疗装置转变成局部药物递送系统。
-
公开(公告)号：US20130211543A1
公开(公告)日：2013-08-15
申请号：US13880204
申请日：2011-10-07
申请人： Muwan Chen , Dang Quang Sven Le , San Hein , Jørgen Kjems , Cody Eric Bünger , Jens Vinge Nygaard
发明人： Muwan Chen , Dang Quang Sven Le , San Hein , Jørgen Kjems , Cody Eric Bünger , Jens Vinge Nygaard
IPC分类号： A61F2/02
CPC分类号： A61F2/02 , A61L27/446 , A61L27/46 , A61L27/54 , A61L27/56 , A61L2300/416 , A61L2300/602 , A61L2430/02 , A61L2430/06 , A61L2430/38
摘要： A three-dimensional hybrid scaffold capable of supporting cell activities such as growth and differentiation, and capable of controlled release of active pharmaceutical ingredients, characterized in that the scaffold comprises a first and a second biocompatible material, said first material shaped as a framework forming one or more open networks of voids, said second material comprising an ion exchange material, said ion exchange material being loaded with one or more active pharmaceutical ingredients.
摘要翻译： 能够支持诸如生长和分化的细胞活性并且能够控制释放活性药物成分的三维杂交支架，其特征在于所述支架包括第一和第二生物相容性材料，所述第一材料形成为骨架形成一个 或更多开放的空隙网络，所述第二材料包括离子交换材料，所述离子交换材料装载有一种或多种活性药物成分。
-
公开(公告)号：US20100272813A1
公开(公告)日：2010-10-28
申请号：US12670043
申请日：2008-07-23
IPC分类号： A61K31/713 , C08B37/08 , A61K9/14 , A61P29/00
CPC分类号： A61K31/713 , A01K2217/058 , A01K2227/105 , A61K9/5161 , A61K47/61 , C07K14/525 , C12N15/111 , C12N15/1136 , C12N2310/14 , C12N2320/32
摘要： The present invention provides nanoparticles for treatment of inflammatory diseases. The nanoparticles preferably comprise chitosan and a siRNA targeting a mRNA encoding a pro-inflammatory cytokine, such as e.g. tnf-alfa. A preferred route of administration of the nanoparticles is by injection intraperitoneally.
摘要翻译： 本发明提供用于治疗炎性疾病的纳米颗粒。 纳米颗粒优选包含壳聚糖和靶向编码前炎症细胞因子的mRNA的siRNA，例如。 tnf-alfa。 纳米颗粒的优选给药途径是通过腹膜内注射。
-
公开(公告)号：US20100267139A1
公开(公告)日：2010-10-21
申请号：US12669112
申请日：2008-07-16
CPC分类号： A61K38/19 , A61K9/5161 , A61K47/59 , A61K47/60 , A61K47/61 , A61K47/645 , A61K47/6455 , A61K47/6929 , B82Y5/00 , Y10T428/2982
摘要： The present invention relates to nanoparticles comprising osteopontin and a polymer carrier, preferably a cationic carrier. Preferably, the cationic carrier is chitosan. Osteopontin and/or the cationic carrier may have bioactivity and/or the nanoparticle may comprise an additional component with bioactivity. Such additional bioactive component may e.g. be a siRNA. The nanoparticles of the invention may be used for treatment of bone diseases or inflammatory diseases.
摘要翻译： 本发明涉及包含骨桥蛋白和聚合物载体，优选阳离子载体的纳米颗粒。 阳离子载体优选为壳聚糖。 骨桥蛋白和/或阳离子载体可以具有生物活性和/或纳米颗粒可以包含具有生物活性的另外的组分。 这样的另外的生物活性成分可以例如。 成为siRNA。 本发明的纳米颗粒可用于治疗骨疾病或炎性疾病。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)
